NCT03693261

Brief Summary

We hypothesize that human epicardial fat plays a thermogenic role to the myocardium. We hypothesize that epicardial fat may express genes of brown fat and thyroid function that are down-regulated by the presence of coronary artery disease. Because the postulated metabolic role of the epicardial fat, we also hypothesize that the gene expression of these regulatory thermogenic factors is higher in epicardial than subcutaneous fat This will be a cross-sectional study conducted over a one-year period in patients with or without coronary artery disease who require elective cardiac surgery regardless their participation in the study. Study group will be formed by 50 patients with clinically and angiographically established CAD who will undergo coronary artery bypass graft, as part of their standard medical care. Control group will be formed by 10 subjects, randomly selected, who will undergo cardiac surgery for aortic or mitral valve replacement as part of their standard medical care (these patients have no history, clinical signs of CAD, and show normal coronary arteries on coronary angiography). This will be a cross-sectional study conducted over a one-year period in patients with or without coronary artery disease who require elective cardiac surgery regardless their participation in the study. Adipose tissue will be collected during the cardiac surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
43

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2011

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 18, 2011

Completed
6.8 years until next milestone

First Submitted

Initial submission to the registry

September 30, 2018

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 2, 2018

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 15, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 15, 2019

Completed
Last Updated

April 17, 2019

Status Verified

April 1, 2019

Enrollment Period

7.3 years

First QC Date

September 30, 2018

Last Update Submit

April 15, 2019

Conditions

Keywords

epicardial fat

Outcome Measures

Primary Outcomes (1)

  • EAT thermoregulatory genes

    Does human epicardial fat express makers of brown adipose tissue, such UCP-1 and brown adipocyte differentiation transcription factors in subjects with and without coronary artery disease? Does human epicardial fat express type 2 and type 3 deiodinase, thyroid hormones and β-3 adrenergic receptors in subjects with and without coronary artery disease? Is the thermoregulatory function of the human epicardial fat correlated to the presence and severity of coronary artery disease?

    24 hours

Secondary Outcomes (1)

  • Subcutaneous fat genes

    24 hours

Study Arms (2)

Coronary Artery Disease (CAD)

Patients with clinically and angiographically established coronary artery disease (CAD) who require CABG, as part of the standard medical care.

Procedure: Coronary artery bypass grafting (CABG)

controls

Control group will be formed by subjects, randomly selected, who will undergo cardiac surgery for aortic or mitral valve replacement as part of their standard medical care (these patients have no history, clinical signs of CAD, and show normal coronary arteries on coronary angiography).

Procedure: Valve replacement

Interventions

CABG, as part of the standard medical care

Coronary Artery Disease (CAD)

cardiac surgery for aortic or mitral valve replacement as part of their standard medical care

controls

Eligibility Criteria

Age50 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The total number of patients participating in the research will be 60. The study group will be formed by 50 consecutive patients, male and female, age 50-75 years, Caucasian, Hispanic and African American, patients with clinically and angiographically established CAD who will undergo CABG, as part of their standard medical care. The control group will be formed by 10 subjects male and female age 50-75 years, randomly selected, who will undergo cardiac surgery for aortic or mitral valve replacement as part of their standard medical care; these patients have no history, clinical signs of CAD, and show normal coronary arteries on coronary angiography.

You may qualify if:

  • Subjects with clinically and angiographically established CAD
  • Controls: subjects with have no history, clinical signs of CAD, and show normal coronary arteries on coronary angiography, who will undergo cardiac surgery for aortic or mitral valve replacement as part of their standard medical care

You may not qualify if:

  • Patients with heart failure, kidney failure or liver failure, infective disease or cancer will be excluded from the study. Subjects taking glucocorticoids or estrogens or patients currently smoking will be excluded from the study. Patients with mental disorders will also not be included

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Miami

Miami, Florida, 33136, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Adipose tissue will be collected during the cardiac surgery. Epicardial adipose tissue (EAT) biopsy samples (average 0.5-1.0 g) will be taken by cardiac surgeon after anesthesia, before heparin administration, near the proximal tract of the right coronary artery. Each tissue sample will be snap frozen in liquid nitrogen and stored at -80 °C until analysis in a freezer . The subcutaneous fat tissue (SAT) will be harvested at the site of the thoracic wound and preserved in the same manner.

MeSH Terms

Conditions

Coronary Artery Disease

Interventions

Coronary Artery BypassTranscatheter Aortic Valve Replacement

Condition Hierarchy (Ancestors)

Coronary DiseaseMyocardial IschemiaHeart DiseasesCardiovascular DiseasesArteriosclerosisArterial Occlusive DiseasesVascular Diseases

Intervention Hierarchy (Ancestors)

Myocardial RevascularizationCardiac Surgical ProceduresCardiovascular Surgical ProceduresSurgical Procedures, OperativeVascular GraftingVascular Surgical ProceduresThoracic Surgical ProceduresHeart Valve Prosthesis ImplantationProsthesis Implantation

Study Design

Study Type
observational
Observational Model
CASE CROSSOVER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Medicine

Study Record Dates

First Submitted

September 30, 2018

First Posted

October 2, 2018

Study Start

December 18, 2011

Primary Completion

April 15, 2019

Study Completion

April 15, 2019

Last Updated

April 17, 2019

Record last verified: 2019-04

Locations